

clinical protocol:

Epoetin for Anemia of Prematurity




TABLE 1:

	AGE								
	3 days	3 weeks	6 weeks	9 weeks	12 weeks	18 weeks	24 weeks	36 weeks	54 weeks
Iron (mcg/dL)									
28-32 weeks	54 (±34)	12 (±50)	99 (±37)	91 (±26)	90 (±37)	96 (±32)	91 (±35)	81 (±32)	110 (±41)
33-36 weeks	62 (±22)	138 (±37)	101 (±29)	96 (±37)	73 (±27)	86 (±35)	87 (±35)	82 (±34)	95 (±36)

TABLE 2:

		Percentiles								
	Day of Life	3	5	10	25	median	75	90	95	97
Ferritin (ng/mL)	3	27	35	48	80	140	204	279	360	504
	12-14	43	65	89	128	168	243	329	410	421
	24-26	27	44	57	93	153	234	300	355	383
	40-42	17	20	35	62	110	191	290	420	457

TABLE 3:

	26-28 weeks	32-36 weeks	37-41 weeks
TIBC (mcgg/dL)	31 (27-35)	36 (31.5-44)	42 (36-49.5)

References:

1. Maxwell, J. R., & Ohls, R. K. (2019). Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection. *NeoReviews*, 20(11), e622–e635.
2. Aher, S., & Ohlsson, A. (2019). Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. *Cochrane Database of Systematic Reviews*, (2).
3. Ohlsson, A., & Aher, S. M. (2017). Early erythropoiesis-stimulating agents in preterm or low birth weight infants. *Cochrane Database of Systematic Reviews*, 2017(11).
4. Ohls, R. K., Christensen, R. D., Kamath-Rayne, B. D., Rosenberg, A., Wiedmeier, S. E., Roohi, M., ... Lowe, J. R. (2013). A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. *Pediatrics*, 132(1), 119–127.
5. Haiden, N., Klebermass, K., Cardona, F., Schwindt, J., Berger, A., Kohlhauser-Vollmuth, C., ... Pollak, A. (2006). A randomized, controlled trial of the effects of adding vitamin B 12 and folate to erythropoietin for the treatment of anemia of prematurity. *Pediatrics*, 118(1), 180–188.
6. Haiden, N., Schwindt, J., Cardona, F., Berger, A., Klebermass, K., Wald, M., ... Pollak, A. (2006). Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants. *Pediatrics*, 118(5), 2004–2013.
7. Meyer, M. P., Haworth, C., Meyer, J. H., & Commerford, A. (1996). A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. *Journal of Pediatrics*, 129(2), 258–263.
8. Warwood, T. L., Ohls, R. K., Wiedmeier, S. E., Lambert, D. K., Jones, C., Scoffield, S. H., ... Christensen, R. D. (2005). Single-dose darbepoetin administration to anemic preterm neonates. *Journal of Perinatology*, 25(11), 725–730.
9. Patel, S., & Ohls, R. K. (2015). Darbepoetin administration in Term and Preterm Neonates. *Clinics in Perinatology*, 42(3), 557
10. Obladen M, et al. Venous and arterial hematologic profiles of very low birth weight infants. European Multicenter rhEPO Study Group. *Pediatrics*. 2000;106:710
11. Beard, J., deRegnier, R.-A., Shaw, M. D., Rao, R. & Georgieff, M. Diagnosis of Iron Deficiency in Infants. *Lab Med* 38, 103–108 (2007).
12. Halliday, H. L., Lappin, T. R. J. & McClure, G. Iron Status of the Preterm Infant during the First Year of Life. *Neonatology* 45, 228–235 (1984).

*The information contained in this document is intended as a **SAMPLE ONLY** to assist your facility. All final content is the responsibility of the facility and should be based on specific facility indicators. Any references provided are solely to support your review and validation of the information.*